Clinical evidence for tDCS
tDCS neuromodulation has growing support in randomized controlled trials and landmark meta-analyses. Here we gather what the literature shows — factually, with its strengths and limits — by condition.
How to read this evidence
Serious clinical information needs context. So we present the results with the same caveats found in the original literature.
- Complementary, supervised therapy. tDCS is presented as an adjunctive treatment, indicated and monitored by a healthcare professional — never as unsupervised home use.
- Non-promissory results. We describe symptom reduction or modulation, generally with small-to-moderate effect sizes. We do not promise cure, guaranteed remission or absence of risk.
- Evidence by analogy to the device. Most studies used research stimulators from other brands; no result is attributed specifically to HDCstim.
- No Level A. International guidelines assign at most Level B (probable efficacy) to some indications — none receives Level A (definite efficacy).
Evidence by condition
A summary by condition. Tap each one to see the studies, montages and caveats in detail.
Depression
Meta-analysis: improvement greater than placebo (Hedges' g ≈ 0.37); the IFCN 2017 guideline assigns Level B (probable efficacy).
Chronic pain & Fibromyalgia
RCTs and meta-analyses associate M1 tDCS with pain reduction; guidelines diverge (EAN inconclusive · IFCN Level B).
Post-stroke rehabilitation
Adjuvant benefit in specific domains — naming (aphasia) and dysphagia; motor function is not established.
What the literature brings together
Safety and tolerability
In the reviewed clinical literature (more than 1,300 individuals), no permanent or serious side effects were reported. The effects described are mild and transient — tingling, itching or redness under the electrodes and, less frequently, mild headache or fatigue. There are rare signals for professional assessment, such as hypomania in people with bipolar disorder and rare skin reactions.
About the device and doses
For therapeutic use, the current is up to 2 mA and sessions last about 20 minutes; higher currents or longer times are reserved for research contexts. Most cited studies used research stimulators from other brands — the evidence is extrapolated by analogy, and no result should be attributed specifically to HDCstim.
Key sources
A selection of the studies and guidelines underpinning the content of this site.
- Shiozawa P, et al. tDCS for major depression: meta-analysis. Int J Neuropsychopharmacol. 2014;17:1443–1452.
- Lefaucheur J-P, et al. Evidence-based guidelines on tDCS (IFCN). Clin Neurophysiol. 2017;128(1):56–92.
- Woodham RD, et al. Home-based tDCS for major depression (RCT). Nat Med. 2025;31:87–95.
- Valle A, et al. Anodal tDCS for fibromyalgia (RCT). J Pain Manag. 2009;2(3):353–361.
- Hou W-H, Wang T-Y, Kang J-H. Non-invasive brain stimulation in fibromyalgia: meta-analysis. Rheumatology (Oxford). 2016;55(8):1507–1517.
- Cruccu G, et al. EAN guidelines on neurostimulation for chronic pain. Eur J Neurol. 2016;23:1489–1499.
- Moshfeghinia R, et al. tDCS for fibromyalgia: meta-analysis. BMC Neurol. 2023;23:395.
- Elsner B, Kugler J, Mehrholz J. tDCS for post-stroke aphasia. J Neuroeng Rehabil. 2020;17:88.
- He K, et al. tDCS for post-stroke dysphagia: meta-analysis. J Clin Med. 2022;11(8):2297.
- Lefaucheur J-P. tDCS clinical trial database. Neurophysiol Clin. 2016;46(4–5):319–398.
Informational, non-promissory content. tDCS is a complementary therapy under professional supervision; results vary between individuals.
Questions about your case?
The decision to use tDCS is made on an individual basis and must be taken by a healthcare professional. Talk to a Mind Health specialist — with no commitment.